DBV Technologies Stock Rises to €3.43 Despite Lowered Price Target
The stock of the French biotech company increased by 2.2% to €3.43 mid-session in a rising Parisian market. The previous day, Kempen maintained its buy recommendation while reducing its price target from €11 to €9. This movement occurred a few days after the publication of the first quarter 2026 results.
Kempen adjusted its opinion on DBV Technologies on May 4. The Dutch firm continues to recommend buying but has lowered its target from €11 to €9. Based on the current price of €3.43, the implied upside potential remains over 160%. This revision follows the quarterly publication on April 30, which reported a net loss of $47.6 million and a significant increase in R&D expenses. The biotech also confirmed two regulatory filings in 2026 for its Viaskin Peanut patch for age groups 4-7 years and 1-3 years. The financial calendar includes the mixed general meeting on June 3, 2026, followed by the half-year results on July 29.
Price Stuck Between Support at €3.34 and MM50 at €3.60
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock is trading in a narrow range. The price at €3.43 is just above the support at €3.34, already tested at the beginning of the month, and remains below the 50-day moving average at €3.60. The 200-day moving average at €2.79, however, confirms the underlying bullish trend, with a performance of 125.5% over the year. The RSI at 43 remains neutral and does not indicate either overselling or overbuying. Today's rebound is in the lower part of the Bollinger Bands (lower boundary at €3.30), without breaching any major technical level. The next concrete appointment is the general meeting on June 3, 2026, before the half-year results on July 29.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
